Bay Street News, 2024

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support […]

Technology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products […]

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage […]

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating […]

At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% […]

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses […]

– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional […]

TORONTO, June 14, 2024 (GLOBE NEWSWIRE) — Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced […]

RAPID CITY, S.D., June 14, 2024 (GLOBE NEWSWIRE) — Black Hills Corp. (NYSE: BKH) today announced its Colorado electric utility, […]

HAMMOND, La., June 14, 2024 (GLOBE NEWSWIRE) — On June 14, 2024 the Board of Directors of First Guaranty Bancshares, […]